Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sales For 27 JPMA Member Companies Increase By 3.8 Percent In FY2007

This article was originally published in PharmAsia News

Executive Summary

The Japan Pharmaceutical Manufacturers Association summarized results of 27 Tokyo Stock Exchange publicly traded member companies for fiscal year 2007. Total sales increased 3.8 percent to ¥6.82 trillion. Sales in the overseas market, increasing by 9.1 percent compared to the 1.3 percent increase in the Japanese domestic market, drove the growth. Compared to sales, income increased by a mere 2.5 percent to ¥1.371 trillion. M&A activities, licensing payments and especially R&D expenses, which increased by 16.5 percent to ¥1.1989 trillion, all resulted in a lower income. JPMA estimates a further increase in revenue due to more expansions in overseas markets for some major drugs, and a double digit decrease in income due to continuous R&D expenses. . (Click here for more - Japanese language

Latest Headlines
See All
UsernamePublicRestriction

Register

SC068886

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel